English
Français
Deutsch
Español
Italiano
Português
日本語
한국어
Русский
Home
Nov 03, 2023
New study shows true impact of endotoxins in 3D in vitro models
16 March 2023 11:14 Darling Ingredients’ health brand Rousselot, a global supplier in collagen-based solutions, announced that a new study has found that utilisation of highly purified gelatin
16 March 2023
11:14
Darling Ingredients’ health brand Rousselot, a global supplier in collagen-based solutions, announced that a new study has found that utilisation of highly purified gelatin biomaterials for 3D in vitro models can significantly enhance the reliability and reproducibility in these models, creating new possibilities for replacing preclinical animal trials.
“This study revealed that 3D models of novel breast cancer immunotherapies display clear therapeutic efficacy differences depending on the level of endotoxins in gelatins and methacryloyl gelatins (GelMA) used in in vitro systems. Biomaterials with low endotoxin content could lead to a more accurate representation of the safety and potency of novel therapeutics. This can improve the validity of 3D in vitro models and help to reduce animal testing,” said Dr. Kathleen Jacobs, global regulatory affairs director, Rousselot.
The joint study done by the University of Twente, The Netherlands, and Rousselot Biomedical investigated for the first time the impact of endotoxins on 3D breast tumor-immune cancer models. The research compared 3D models using standard gelatins and GelMAs or Rousselot’s X-PURE gelatin and X-PURE GelMA – purified biomaterials with low endotoxin levels (<10 EU/g).
The study demonstrated that endotoxin levels had a marked effect on the validity of the 3D-printed model in three aspects:
Image 1: Illustration to show how the presence of endotoxins impacts the credibility of 3D models. This figure is a modified version of the original graphic in Heinrich, M. A., Heinrich, L., Ankone, M. J. K., Vergauwen, B., & Prakash, J. (2023).
Recent changes in European Union and US Food and Drug Administration (FDA) legislation, combined with increased ethical considerations and efficacy demands, are driving the rapid replacement of pre-clinical animal trials with 3D biofabrication models.
Dr. Bjorn Vergauwen, scientific director, product and process development, Rousselot concluded: “The use of purified biomaterials such as Rousselot’s X-Pure or X-Pure GelMA in in vitro 3D models is critical in producing a biologically relevant environment, while also helping to reduce the costs, time and ethical concerns associated with drug development.”
16 March 2023
11:14
Darling Ingredients’ health brand Rousselot, a global supplier in collagen-based solutions, announced that a new study has found that utilisation of highly purified gelatin biomaterials for 3D in vitro models can significantly enhance the reliability and reproducibility in these models, creating new possibilities for replacing preclinical animal trials. A joint study by the University of TwenteThe study measured the effectRecent changes in the EU and US FDA legislationInflammatory reaction:Receptivity of immune cells to cancer cellsReliability of therapeutic outcomes